(3D) Ultrasound Imaging Liver and Kidney
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03844399 |
Recruitment Status :
Recruiting
First Posted : February 18, 2019
Last Update Posted : April 27, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Liver Cancer Kidney Cancer | Device: Ablation Device: Biopsy |
Study Type : | Observational |
Estimated Enrollment : | 40 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Use of 3-Dimensional (3D) Ultrasound Imaging to Guide the Treatment of Abdominal Tumours Using Focal Ablation or Biopsies |
Actual Study Start Date : | October 3, 2020 |
Estimated Primary Completion Date : | April 6, 2022 |
Estimated Study Completion Date : | July 2022 |

Group/Cohort | Intervention/treatment |
---|---|
Patients
Cancer patients who are scheduled to undergo an ablation or biopsy of a liver or kidney tumour
|
Device: Ablation
The medical device will passively record image data during the standard care ablation Device: Biopsy The medical device will passively record image data during the standard care biopsy |
- Needle Guidance Intervention [ Time Frame: April 2020 ]The objective of this study is to use 3D ultrasound in addition to standard care ultrasound to guide the ablation needles in destroying focal tumours within the diseased organ

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- • Patients who are scheduled for standard care liver or kidney ablation or biopsy
Exclusion Criteria:
- None

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03844399
Contact: Aaron Fenster | 5199315777 | afenster@uwo.ca |
Canada, Ontario | |
Victoria Hospital | Recruiting |
London, Ontario, Canada, N6A 5W9 | |
Contact: Derek Cool, MD/PhD 5196858500 ext 54965 |
Responsible Party: | Western University, Canada |
ClinicalTrials.gov Identifier: | NCT03844399 |
Other Study ID Numbers: |
6319 |
First Posted: | February 18, 2019 Key Record Dates |
Last Update Posted: | April 27, 2021 |
Last Verified: | April 2021 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Diagnostic Intervention 3D Ultrasound |
Kidney Neoplasms Neoplasms by Site Neoplasms Urologic Neoplasms |
Urogenital Neoplasms Kidney Diseases Urologic Diseases |